Device cost-effectiveness studies should focus on "direct" provider savings -- Corning HTA exec.
This article was originally published in The Gray Sheet
DEVICE OUTCOME STUDY PUBLICATION IN PEER-REVIEWED JOURNALS CAN BE "CRITICAL" to securing insurance coverage for new technology, Corning HTA President Michael Strauss, MD, said at a Sept. 12-13 meeting on device outcomes in Washington, D.C. cosponsored by the Health Industry Manufacturers Association and Corning HTA. Peer-reviewed publication of outcome studies "is one of the few mechanisms" manufacturers "have to communicate outcomes information," Strauss added.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.